



MAXINE DUNITZ NEUROSURGICAL INSTITUTE

8631 West Third Street – 800E
Los Angeles, California 90048
Tel: (310) 423-7900 ♦ Fax: (310) 423-0810

**A PHASE II TRIAL OF TUMOR LYSATE-PULSED DENDRITIC CELL
IMMUNOTHERAPY FOR PATIENTS WITH ATYPICAL OR MALIGNANT,
PRIMARY OR METASTATIC BRAIN TUMORS OF THE CENTRAL NERVOUS
SYSTEM**

This study is being done to determine whether vaccinations with the subject's own immune cells called "dendritic cells" (after they are mixed with proteins from the subject's brain tumor cells) can activate the subject's immune system to fight their brain tumor. Tumor cells are taken at the time of surgery and are frozen and thawed to separate protein segments that are unique to that tumor. These proteins will be added to another culture of the subject's dendritic cells grown from their blood, combined together, then re-injected back into the subject's body.

Dendritic cells are a small group of cells contained in everyone's white blood cell population. These cells are responsible for letting the immune system know that something foreign, like bacteria, or a tumor, is in the body. Dendritic cells help the body ward off disease by alerting the immune system.

The purpose of this study is to evaluate and test the safety of subcutaneous (beneath the skin) injections of the subject's own dendritic cells that have been removed from the subject's peripheral blood and cultured with tumor protein fragments from the subject's brain tumor.

Contact Person:

John Yu, MD
Director, Surgical Neuro-oncology
Co-Director, Gamma Knife Center
yuj@cshs.org
(310) 423-7900